PodcastIntel
Sign in Get Started Free
HCPLive
HCPLive

Brepocitinib Improves Cutaneous Sarcoidosis by Week 4: Aaron Mangold, MD

Oct 9, 2026 · 0:06:15
Listen to Episode
✨ AI Summary
  • Brepocitinib showed rapid, dose-dependent improvement in cutaneous sarcoidosis.
  • Phase 2 BEACON trial interim analysis presented at EADV Congress 2026.
  • Oral selective TYK2/JAK1 inhibitor targets cutaneous sarcoidosis activity.

Guests on This Episode

AM
Aaron Mangold
researcher (ORCID 0000-0001-6873-1705) · 1 podcast appearance
›

More from HCPLive

HCPLive
Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites
Oct 12, 2026 · 0:03:18
HCPLive
Targeting Senescent Cells in Actinic Keratosis With RLS-1496
Oct 12, 2026 · 0:04:25
HCPLive
Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD
Oct 12, 2026 · 0:03:33
HCPLive
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
Oct 12, 2026 · 0:06:00
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to HCPLive and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →